Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 79,410 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions: Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19
Interventions: PUL-042 Inhalation Solution, Placebo; Drug
Lead sponsor: Pulmotect, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Orange, California • San Bernardino, California • Coral Gables, Florida + 10 more

Conditions: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Interventions: ND-L02-s0201 Injection; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Stimulant Use Disorder
Interventions: Smartphone digital therapeutic system; Device
Lead sponsor: DynamiCare Health; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: decitabine; Drug
Lead sponsor: California Cancer Consortium; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California • Sacramento, California

Conditions: Postoperative Delirium, Postoperative Cognitive Dysfunction
Interventions: CN-105, Placebo; Drug
Lead sponsor: Miles Berger, MD PhD; Other
Eligibility: 60 Years and older
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bipolar Disorder
Interventions: pramipexole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
Interventions: Axitinib, Pembrolizumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more

Conditions: Asthma
Interventions: Albuterol-HFA-MDI, Albuterol-HFA-BAI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 7 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Huntington Beach, California • Lakewood, Colorado • Minneapolis, Minnesota + 2 more

Conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions: Vimseltinib, Placebo; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 11
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Hematologic and Lymphocytic Disorder
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Itacitinib, Tacrolimus, Thiotepa; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm, Recurrent Adult Brain Neoplasm
Interventions: Cilengitide, Clinical Observation, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: Clarithromycin, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy; Biological · Procedure
Lead sponsor: Ashutosh Kumar Tewari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyponatremia, Inappropriate ADH Syndrome
Interventions: Urea; Drug
Lead sponsor: Helbert Rondon Berrios, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: INCAGN01876, retifanlimab; Biological
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more

Conditions: Pain
Interventions: Codeine Sulfate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Coronary Artery Disease, Heart Valve Disease
Interventions: CDI 1000 COM and INVOS 5100; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Orange, California

Conditions: COVID19, ARDS
Interventions: CK0802, Placebo; Biological · Drug
Lead sponsor: Cellenkos, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more

Conditions: Hepatic Impairment, Liver Disease, Pharmacokinetics
Interventions: Elafibranor; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Pancreatic Cancer, Cancer of the Pancreas
Interventions: huCART-meso cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Benign Prostatic Hyperplasia
Interventions: placebo, sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 35 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Laguna Woods, California • Newport Beach, California

Search by objective public record fields.

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Smartphone Services for Stimulant Use Disorder

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

Cognitive Enhancement in Bipolar Disorder

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Itacitinib for the Prevention of Graft Versus Host Disease

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Urea for Chronic Hyponatremia

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Food Effect Study of Codeine Sulfate

A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

CAR T Cell Immunotherapy for Pancreatic Cancer

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin